Clinical Trial Update: A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation [Phase 1, Phase 2]

View source ↗

Summary

A study investigating RC48-ADC in combination with Pyrotinib for locally advanced or metastatic non-small cell lung cancer with HER2 mutation (Phase 1/Phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pyrotinib (pyrotinib)
• RC48-ADC (Disitamab Vedotin)

Snippet

Sponsor: RemeGen Co., Ltd. | Conditions: Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: UNKNOWN